SCHEMBL934610

SCHEMBL934610

N#Cc1cccc(CCC(N)=O)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 4/20 0.55
FFAR4 Q5NUL3 1/20 0.55
CNR1 P21554 1/20 0.48
MEP1A Q16819 1/20 0.48
MEP1B Q16820 1/20 0.48
PLA2G10 O15496 1/20 0.47
PLA2G2A P14555 1/20 0.47
EPHX1 P07099 1/20 0.47
MAPK8 P45983 1/20 0.47
LMNA P02545 1/20 0.46
GLA P06280 1/20 0.45
ADRA1D P25100 1/20 0.45
GSK3B P49841 1/20 0.45
FOLH1 Q04609 1/20 0.45
SIRT2 Q8IXJ6 1/20 0.44
SIRT1 Q96EB6 1/20 0.44
ERCC1 P07992 1/20 0.44
ERCC4 Q92889 1/20 0.44
HTR2B P41595 1/20 0.43
VNN1 O95497 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12500258 0.92 FFAR1 (0.50) FFAR1FFAR4CNR1MEP1AMEP1B
SCHEMBL7335965 0.86 FFAR1 (0.57) FFAR1FFAR4CNR1MEP1AMEP1B
SCHEMBL3491515 0.85 FFAR1 (0.72) FFAR1FFAR4CNR1PLA2G10PLA2G2A
SCHEMBL6364918 0.83 FFAR1 (0.55) FFAR1FFAR4CNR1MEP1AMEP1B
SCHEMBL2411845 0.83 FFAR1 (0.55) FFAR1FFAR4CNR1MEP1AMEP1B
SCHEMBL6714339 0.83 MAPK8 (0.56) FFAR1FFAR4CNR1MEP1AMEP1B
SCHEMBL30489963 0.83 MAPK8 (0.56) FFAR1FFAR4CNR1MEP1AMEP1B
SCHEMBL27322168 0.81 FFAR1 (0.52) FFAR1FFAR4CNR1MEP1AMEP1B
SCHEMBL2154019 0.80 GLA (0.53) FFAR1FFAR4CNR1MEP1AMEP1B
SCHEMBL3109008 0.80 FFAR1 (0.54) FFAR1FFAR4CNR1MEP1AMEP1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1341755-A1 CARBOXYLIC ACID AMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOEMBOLIC DISEASES AND TUMOURS MERCK PATENT GmbH (DE) 2003-09-10 EP claimed
WO-2002048099-A1 CARBOXYLIC ACID AMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOEMBOLIC DISEASES AND TUMOURS MERCK PATENT GMBH (DE) 2002-06-20 WO claimed
WO-2023226965-A1 ROCK INHIBITORS AND USES THEREOF DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2023-11-30 WO disclosed
EP-2454243-A2 TETRAZOLE DERIVATIVES Merck Serono SA (CH) 2012-05-23 EP disclosed
US-20120115869-A1 TETRAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2012-05-10 US disclosed
WO-2011006935-A2 TETRAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115869-A1 TETRAZOLE DERIVATIVES TSLP, IL5, CMA1 FFAR1 924/4885FFAR4 923/4885CNR1 2036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.